BiolineRx
Committed to developing novel compounds in oncology that will deliver life-changing innovations for patients.
Launch date
Employees
Market cap
€49.1m
Enterprise valuation
€41m (Public information from Sep 2024)
Share price
$0.62 BLRX
Jerusalem Jerusalem District (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | 4.8m | 25.0m | 24.0m | 36.1m |
| % growth | - | - | - | - | 421 % | (4 %) | 51 % |
| EBITDA | (22.3m) | (23.4m) | (22.1m) | (39.4m) | (39.8m) | (32.8m) | - |
| % EBITDA margin | - | - | - | (821 %) | (159 %) | (137 %) | - |
| Profit | (30.0m) | (27.1m) | (25.0m) | (60.6m) | (18.6m) | (38.6m) | (35.1m) |
| % profit margin | - | - | - | (1263 %) | (74 %) | (161 %) | (97 %) |
| EV / revenue | - | - | - | 24.0x | 2.2x | 2.3x | 1.5x |
| EV / EBITDA | -2.7x | -4.2x | -1.3x | -2.9x | -1.4x | -1.7x | - |
| R&D budget | 18.2m | 19.5m | 17.6m | 12.5m | - | - | - |
| R&D % of revenue | - | - | - | 261 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $4.0m | Early VC | |
$9.0m | Early VC | ||
| N/A | N/A | IPO | |
| N/A | N/A | IPO | |
| N/A | $15.0m | Post IPO Equity | |
$8.0m | Post IPO Equity | ||
| N/A | $24.1m | Post IPO Equity | |
| N/A | $25.0m | Post IPO Equity | |
| N/A | $28.8m | Post IPO Equity | |
* | $9.6m | Post IPO Equity | |
* | N/A | $15.4m | Post IPO Equity |
* | N/A | $13.4m | Post IPO Equity |
| N/A | $10.0m | Post IPO Equity | |
* | $10.0m | Post IPO Debt | |
* | $20.0m | Post IPO Debt | |
| Total Funding | €11.8m | ||
Related Content
Recent News about BiolineRx
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by BiolineRx
Edit
ACQUISITION by BiolineRx Mar 2017